Oncoptpeptides - Bring hope through science

Bringing hope through science

Released

Interim report Q3 2022

”Oncopeptides enters a new phase with EMA approval and launch of Pepaxti in Germany as the first market”

CEO Jakob Lindberg

 

See the Webcast


For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

 

Year-end report 2022,
February 16, 2023

Profile image
Jakob Lindberg, CEO Oncopeptides.com

CEO Jakob Lindberg interviewed by Di.TV regarding the Q3 report and the EU and US market

On November 9, 2022, CEO Jakob Lindberg was interviewed by Börsmorgon in the Swedish Dagens Industri Di.TV regarding the Q3 report and the EU and US market. See the interview by clicking the link below. The interview is in Swedish.

To the interview in Di.TV

Events Oncopeptides

Upcoming events

View calendar

Tyska lanseringen av Pepaxti - presentation

Fredagen den 21 oktober kl.14.00, 2022, håller Oncopeptides en presskonferens för att prata om den tyska lanseringen av Pepaxti®.

Se presentationen i PDF här

Jakob Lindberg

European Commission approves Oncopeptides' Pepaxti

“The approval of Pepaxti in Europe is foundational for Oncopeptides, and brings excellent news for patients and shareholders,” says Jakob. “Despite the introduction of novel therapies, patients with triple class refractory disease have a high unmet medical need, since their treatment options ultimately become exhausted.”

Link to the press release

Link to Sep 22 ODAC meeting and Briefing Book

The US Food and Drug Administration (FDA) has published the Briefing Book for the Oncologic Drugs Advisory Committee (ODAC) meeting on September 22, 2022. The purpose of the meeting is to obtain the advisory committee's input regarding the benefit/risk of Pepaxto® (melphalan flufenamide, also called melflufen) for the currently indicated patient population.

Link to the Briefing Book

Link to the public ODAC meeting (starts 19:50 CET, Sep 22)

Read the press release about the Briefing Book

Webcast - update from the ODAC meeting

September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.

Investors, analysts and media were invited to listen to a webcast presentation and participate in a following Q&A session on September 26, at 14:00 (CET). The webcast was recorded.

Link to the webcast and phone numbers

Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU

June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU. 

Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor. 

More info, presentation and the webcast link

Released

Annual Report 2021

Letter from the CEO - Science is leading the way

 

For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

Profile image
Jakob Lindberg, CEO

Letter from the CEO - Science is leading the way

"When I look back at 2021, this has been the most revolutionary year in Oncopeptides’ history"
Jakob Lindberg, CEO

Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US

January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US.

Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).

The event will be hosted by CEO, Jakob Lindberg and CMO, Klaas Bakker. The presentation will be held in English.

More info, dial in numbers and the webcast link

Jakob interviewed by Di.TV - as new CEO about going forward

In conjunction with the anouncement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.

See the interview (Swedish) or read the transcript

Jakob Lindberg, CEO

Jakob Lindberg appointed CEO

On November 15, Oncopeptides announced that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides. Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.

Read the press release

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Oncopeptides vision

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Cultures & Values

We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.

Read more